Prediction of Venous Thrombosis After Fracture Operation: Comparative Analysis of Different Fracture Sites

The goal of this observational study is to analyze the clinical characteristics of patients who develop lower limb deep vein thrombosis (DVT) following fracture surgery, with a focus on comparing different fracture sites. The main question it aims to answer is: How do the clinical characteristics of postoperative DVT vary across different fracture sites? The study will involve 429 patients who have been diagnosed with postoperative lower limb DVT following fracture surgery. Data will be collected on patient demographics, fracture type, surgical approach, thrombus size, number, location, and the occurrence of complications such as pulmonary embolism (PE). Participants will also be evaluated for relevant laboratory markers and clinical factors, including coagulation parameters and inflammatory markers.

By examining how these factors differ across fracture sites and their relationship to thrombus characteristics, this study seeks to better understand the risk factors and clinical course of postoperative DVT in orthopedic patients. The findings will provide valuable insights for improving patient management strategies and reducing the risk of complications such as PE in those undergoing fracture surgery.

Study Overview

• Status: Completed
• Conditions: Fractures

• Study Type: Observational
• Enrollment (Actual): 429

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Foshan, Guangdong, China, 528051
      • Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, 528051, Guangdong, China.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Demographics and Baseline Characteristics: The study population includes both male and female patients, with a focus on identifying how age, sex, and comorbid conditions may influence the development of DVT. Age ranges from 18 to over 90 years, with a significant portion of the cohort being elderly (over 60 years old), a group known to be at higher risk for thrombotic events. The patient cohort also includes individuals with varying body mass indices (BMIs), preoperative comorbidities (such as diabetes, hypertension, and cardiovascular disease), and different surgical approaches.Data Collection: For each patient, a comprehensive dataset was collected, including demographic information (age, sex, BMI), clinical characteristics (fracture type, comorbidities, type of surgical intervention), thrombus characteristics (size, location, number), and postoperative complications (e.g., the presence of pulmonary embolism). In addition, laboratory parameters, such as D-dimer levels, complete blood

Description

Inclusion Criteria:

• (1) Age requirement: ≥18 years old, gender is not limited. (2) Including but not limited to rib fracture, femur fracture, tibia and fibula fracture, ankle fracture and other types of fracture (3) Patients with fractures who have undergone surgical treatment and patients with postoperative complications related to venous thrombosis.

  (3) The patient's clinical data (such as age, gender, fracture type, surgical method, postoperative recovery, etc.) and laboratory data (such as D-dimer, coagulation function, etc.) should be fully available.

  (4) Informed consent: Patients voluntarily participate in this study, sign informed consent, and promise to cooperate with the completion of the evaluation and follow-up in the study.

  (5) Patients with diabetes, hypertension and other comorbidities should be recorded, because these diseases may affect the occurrence of venous thrombosis.

Exclusion Criteria:

• (1) Patients with non-fracture types such as upper limb fracture and spinal fracture are not included.

  (2) Acute patients with symptoms of venous thrombosis such as deep vein thrombosis or pulmonary embolism, or patients with a history of significant thrombosis.

  (3) Patients whose clinical data or laboratory data are incomplete, resulting in no effective analysis.

  (4) Patients currently participating in other clinical trials or interventions. (5) Fracture patients who did not receive surgical treatment or only received conservative treatment.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Upper limb fracture group, lower limb fracture group, trunk fracture group, multiple fracture group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
WBC (White Blood Cell count)	WBC (White Blood Cell count), measured in cells/µL,All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
PLT (Platelet count)	PLT (Platelet count), measured in cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
ANC (Absolute Neutrophil Count)	ANC (Absolute Neutrophil Count), measured in cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
Lymphocyte count	Lymphocyte count, measured in cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
Activated Partial Thromboplastin Time (aPTT)	Activated Partial Thromboplastin Time (aPTT), measured in seconds; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
Fibrinogen	Fibrinogen, measured in mg/dL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
Thrombin Time	Thrombin Time, measured in seconds; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
International Normalized Ratio (INR)	International Normalized Ratio (INR), measured as a ratio,All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024

Collaborators and Investigators

• Sponsor: Foshan Hospital of Traditional Chinese Medicine

Publications and helpful links

General Publications

• Hu Y, Zhu L, Tian X, Duan F. Prevalence of preoperative deep vein thrombosis in long bone fractures of lower limbs: a systematic review and meta-analysis. J Orthop Traumatol. 2023 May 8;24(1):19. doi: 10.1186/s10195-023-00699-2.
• Kobayashi T, Akiyama T, Mawatari M. Predictors of preoperative deep vein thrombosis in hip fractures: A systematic review and meta-analysis. J Orthop Sci. 2023 Jan;28(1):222-232. doi: 10.1016/j.jos.2021.08.013. Epub 2021 Sep 27.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2024
• Primary Completion (Actual): December 31, 2024
• Study Completion (Actual): December 31, 2024

Study Registration Dates

• First Submitted: March 8, 2025
• First Submitted That Met QC Criteria: March 13, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 13, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Wounds and Injuries; Embolism and Thrombosis; Fractures, Bone; Thrombosis; Venous Thrombosis
• Other Study ID Numbers: FoshanTCM User

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No